Amivantamab-vmjw
(Redirected from Amivantamab)
What is Amivantamab-vmjw[edit | edit source]
- Amivantamab-vmjw(Rybrevant) is a low-fucose human immunoglobulin G1-based bispecific antibody directed against the EGF and MET receptors, produced by mammalian cell line (Chinese Hamster Ovary [CHO]) using recombinant DNA technology that has a molecular weight of approximately 148 kDa.
- Amivantamab-vmjw (Rybrevant) injection for intravenous infusion is a sterile, preservative-free, colorless to pale yellow solution in single-dose vials.
- The pH is 5.7.
What are the uses of this medicine?[edit | edit source]
- Amivantamab-vmjw(Rybrevant) is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.
How does this medicine work?[edit | edit source]
- A human bispecific antibody targeting both epidermal growth factor receptor EGFR and hepatocyte growth factor receptor (HGFR; cMet), with potential antineoplastic activity.
- Upon administration, amivantamab simultaneously targets and binds to wild-type or certain mutant forms of both EGFR and cMet expressed on cancer cells, thereby preventing receptor phosphorylation.
- This prevents the activation of both EGFR- and cMet-mediated signaling pathways.
- In addition, binding results in receptor degradation, which further inhibits EGFR- and cMet-mediated signaling.
- JNJ-61186372 also causes antibody-dependent cellular cytotoxicity (ADCC).
- Altogether, this results in the inhibition of tumor cell proliferation.
- EGFR and cMet, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.
Who Should Not Use this medicine?[edit | edit source]
- Use is not recommended in pregnant patients because of its adverse effects on fetus.
Is this medicine FDA approved?[edit | edit source]
- It was approved for use in the United States in 2021.
How should this medicine be used?[edit | edit source]
- Intravenous use.
- Administer via a peripheral line on Week 1 and Week 2.
- Administer weekly for 4 weeks, with the initial dose as a split infusion in Week 1 on Day 1 and Day 2, then administer every 2 weeks thereafter.
Each Rybrevant vial contains 350 mg (50 mg/mL) Amivantamab-vmjw, EDTA disodium salt dihydrate (0.14 mg), L-histidine (2.3 mg), L-histidine hydrochloride monohydrate (8.6 mg), L-methionine (7 mg), polysorbate 80 (4.2 mg), sucrose (595 mg), and water for injection, USP.
What are the dosage forms and brand names of this medicine?[edit | edit source]
- Injection: 350 mg/7 mL (50 mg/mL) solution in a single-dose vial.
- The recommended dosage of Rybrevant is based on baseline body weight and administered as an intravenous infusion after dilution.
- Baseline body weight is less than 80 kg, recommended dose 1050 mg (3 vials).
- Baseline body weight is greater than or equal to 80 kg, recommended dose 1400 mg (4 vials).
- Brand name: Rybrevant(TM)
- Packager: Janssen Biotech, Inc.
- NDC Code(s): 57894-501-00, 57894-501-01
What side effects can this medication cause?[edit | edit source]
- The most common adverse reactions (≥ 20%) were rash, IRR, paronychia, musculoskeletal pain, dyspnea, nausea, fatigue, edema, stomatitis, cough, constipation, and vomiting.
- The most common Grade 3 or 4 laboratory abnormalities (≥ 2%) were decreased lymphocytes, decreased albumin, decreased phosphate, decreased potassium, increased alkaline phosphatase, increased glucose, increased gamma-glutamyl transferase, and decreased sodium.
- It can cause ocular toxicity including keratitis, dry eye symptoms, conjunctival redness, blurred vision, visual impairment, ocular itching, and uveitis.
What special precautions should I follow?[edit | edit source]
- Administer both antihistamine and antipyretic prior to all infusions. Glucocorticoid administration required for Week 1, Days 1 and 2 doses only and as necessary for subsequent infusions.
What to do in case of emergency/overdose?[edit | edit source]
- Data regarding overdoses of Amivantamab-vmjw are not readily available. Patients experiencing an overdose should be treated with symptomatic and supportive measures.
- In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.
- Overdose related information is also available online at poisonhelp.org/help.
- In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.
Can this medicine be used in pregnancy?[edit | edit source]
- Based on its mechanism of action and findings from animal models, Amivantamab-vmjw can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to the fetus.
- Advise female patients of reproductive potential to use effective contraception during treatment and for 3 months after the final dose of Amivantamab-vmjw.
Can this medicine be used in children?[edit | edit source]
- The safety and efficacy of Rybrevant have not been established in pediatric patients.
What should I know about storage and disposal of this medication?[edit | edit source]
- Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze.
Amivantamab-vmjw Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Deepika vegiraju